Improved understanding of peripheral T-cell lymphomas

ONCOLOGY

Volumn 24, Issue 7, 2010, Pages

  Duvic, Madeline ^a  

^a University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BORTEZOMIB; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISTODAX; METHOTREXATE; NUCLEAR MATRIX PROTEIN; PRALATREXATE; PREDNISONE; ROMIDEPSIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VORINOSTAT;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHILDHOOD CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG SCREENING; GENE TRANSLOCATION; GENETIC DISORDER; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JAPAN; LARGE CELL LYMPHOMA; LYMPHOCYTE; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; PROTEIN EXPRESSION; RARE DISEASE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; T CELL LEUKEMIA;

EID: 77958047559     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. The Non-Hodgkins Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkins lymphoma. Blood 89:3909-3918, 1997.
2. The International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
3. Savage KJ, Harris NL, Vose JM, et al: ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008.
4. Talpur R, Jones DM, Alencar AJ, et al: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126:575-583, 2006.
5. Fischer P, Nacheva E, Mason DY, et al: A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkins lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 72:234-240, 1988.
6. Mason DY, Bastard C, Rimokh R, et al: CD30-positive large cell lymphomas (Ki-1 lymphoma) are associated with a chromosomal translocation involving 5q35. Br J Haematol 74:161-168, 1990.
7. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkins lymphoma. Science 263:1281-1284, 1994.
8. Sarris AH, Luthra R, Papadimitracopoulou V, et al: Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkins lymphomas, Hodgkins disease, or lymphomatoid papulosis. Blood 88:1771-1779, 1996.
9. Falini B, Pileri S, Zinzani PL, et al: ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 93:2697-2706, 1999. (Pubitemid 29181203)
10. Paulli M, Berti E, Boveri E, et al: Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 29:1223-1230, 1998. (Pubitemid 28525521)
11. Duvic M, Reddy SA, Pinter-Brown L, et al: A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15:6217-6224, 2009.
12. OConnor OA, Horwitz S, Hamlin P, et al: Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357-4364, 2009.
13. Piekarz RL, Frye R, Turner M, et al: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. 27:5410-5417, 2009.
14. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004. (Pubitemid 38970553)
15. Brugières L, Pacquement H, Le Deley MC, et al: Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 27: 5056-5061, 2009.
16. Fanin R, Ruiz de Elvira MC, Sperotto A, et al: Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: Analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 23:437-442, 1999.
17. Le Gouill S, Milpied N, Buzyn A, et al: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264-2271, 2008.